Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Melanoma Management|September 8, 2018
Intratumoral talimogene laherparepvec therapy in melanomaKevin B Kim
Cancer|August 24, 2012
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?Kevin B Kim
Clinical & Experimental Metastasis|June 27, 2024
Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approachesKevin B Kim
Oncology (Williston Park, N.Y.)|September 4, 2014
The past, present, and future of melanoma therapyKevin B Kim
The Lancet. Oncology|February 4, 2014
PFS as a surrogate for overall survival in metastatic melanomaKevin B Kim
Chinese Clinical Oncology|April 6, 2015
Treatment of KIT-mutated metastatic mucosal melanomaKevin B Kim, Anas Alrwas
Clinical & Experimental Metastasis|July 19, 2018
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugsThein Swe, Kevin B Kim
Melanoma Research|December 4, 2004
Biochemotherapy in patients with advanced vulvovaginal mucosal melanomaMandy S Harting, Kevin B Kim
Expert Opinion on Pharmacotherapy|April 12, 2014
Dabrafenib for the treatment of melanomaRodabe N Amaria, Kevin B Kim
Expert Opinion on Investigational Drugs|March 8, 2012
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanomaSapna P Patel, Kevin B Kim
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Melanoma Management|September 8, 2018
Intratumoral talimogene laherparepvec therapy in melanomaKevin B Kim
Cancer|August 24, 2012
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?Kevin B Kim
Clinical & Experimental Metastasis|June 27, 2024
Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approachesKevin B Kim
Oncology (Williston Park, N.Y.)|September 4, 2014
The past, present, and future of melanoma therapyKevin B Kim
The Lancet. Oncology|February 4, 2014
PFS as a surrogate for overall survival in metastatic melanomaKevin B Kim
Chinese Clinical Oncology|April 6, 2015
Treatment of KIT-mutated metastatic mucosal melanomaKevin B Kim, Anas Alrwas
Clinical & Experimental Metastasis|July 19, 2018
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugsThein Swe, Kevin B Kim
Melanoma Research|December 4, 2004
Biochemotherapy in patients with advanced vulvovaginal mucosal melanomaMandy S Harting, Kevin B Kim
Expert Opinion on Pharmacotherapy|April 12, 2014
Dabrafenib for the treatment of melanomaRodabe N Amaria, Kevin B Kim
Expert Opinion on Investigational Drugs|March 8, 2012
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanomaSapna P Patel, Kevin B Kim
Pageof 14